Sutelkta

Sutelkta is a brand name for the drug known generically as palovarotene. It is a medication used to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder characterized by the progressive transformation of soft connective tissues, such as muscles and tendons, into bone. This abnormal bone formation can lead to severe disability, pain, and immobility. Sutelkta works by targeting a specific pathway involved in the abnormal bone development seen in FOP. It is an oral medication that is taken once a day. The approval of Sutelkta marked a significant development in the treatment of FOP, as it is the first medication specifically approved for this condition. Clinical trials have shown that Sutelkta can reduce the rate of new heterotopic ossification, which is the formation of bone in abnormal locations. However, like all medications, Sutelkta can cause side effects, and its use should be closely monitored by a healthcare professional. The drug is typically prescribed by specialists experienced in managing rare genetic disorders.